Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 5,430,000 shares, a decline of 7.8% from the January 31st total of 5,890,000 shares. Approximately 7.5% of the company’s shares are short sold. Based on an average trading volume of 463,700 shares, the short-interest ratio is currently 11.7 days.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. TheStreet raised shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a research report on Tuesday, December 27th. Citigroup lowered their price objective on shares of Integra LifeSciences from $60.00 to $59.00 and set a “neutral” rating for the company in a research note on Thursday, February 23rd. Truist Financial boosted their price objective on shares of Integra LifeSciences from $52.00 to $58.00 and gave the company a “hold” rating in a research note on Tuesday, December 20th. Finally, Morgan Stanley boosted their price objective on shares of Integra LifeSciences from $50.00 to $59.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $58.17.
Integra LifeSciences Stock Down 0.5 %
Shares of Integra LifeSciences stock opened at $54.27 on Wednesday. The company has a fifty day moving average price of $57.06 and a 200 day moving average price of $52.17. The company has a current ratio of 3.62, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. Integra LifeSciences has a twelve month low of $40.67 and a twelve month high of $67.89. The stock has a market cap of $4.43 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.59 and a beta of 1.13.
Insiders Place Their Bets
In other Integra LifeSciences news, EVP Lisa Evoli sold 3,767 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the transaction, the executive vice president now owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.20% of the stock is owned by corporate insiders.
Institutional Trading of Integra LifeSciences
Institutional investors have recently added to or reduced their stakes in the business. Ronald Blue Trust Inc. lifted its holdings in Integra LifeSciences by 118.0% in the 4th quarter. Ronald Blue Trust Inc. now owns 641 shares of the life sciences company’s stock worth $27,000 after buying an additional 347 shares in the last quarter. Wipfli Financial Advisors LLC acquired a new position in Integra LifeSciences in the 3rd quarter worth $29,000. Neo Ivy Capital Management acquired a new position in Integra LifeSciences in the 3rd quarter worth $30,000. Fifth Third Bancorp lifted its holdings in Integra LifeSciences by 40.8% in the 4th quarter. Fifth Third Bancorp now owns 631 shares of the life sciences company’s stock worth $35,000 after buying an additional 183 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Integra LifeSciences by 595.7% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,294 shares of the life sciences company’s stock worth $55,000 after buying an additional 1,108 shares in the last quarter. 87.60% of the stock is owned by hedge funds and other institutional investors.
About Integra LifeSciences
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.